Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The kinin system in inflammation

J M Stewart1

  • 1University of Colorado School of Medicine, Department of Biochemistry, Denver 80262.

Agents and Actions. Supplements
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Transient immediate orthostatic hypotension' is preferable to 'initial' orthostatic hypotension.

Autonomic neuroscience : basic & clinical·2025
Same author

Combination Treatment with Antigen-Specific Dual-Sized Microparticle System Plus Anti-CD3 Immunotherapy Fails to Synergize to Improve Late-Stage Type 1 Diabetes Prevention in Nonobese Diabetic Mice.

ACS biomaterials science & engineering·2020
Same author

Engineering immunomodulatory biomaterials for type 1 diabetes.

Nature reviews. Materials·2020
Same author

First Report of Colletotrichum chlorophyti Infecting Soybean Seed in Arkansas, United States.

Plant disease·2019
Same author

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Investigational new drugs·2017
Same author

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Investigational new drugs·2017
Same journal

Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

Agents and actions. Supplements·1998
Same journal

Immunomodulation of Crohn's disease by interleukin-10.

Agents and actions. Supplements·1998
Same journal

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

Agents and actions. Supplements·1998
Same journal

Symposium new drugs for inflammatory, allergic and immunologic disease.

Agents and actions. Supplements·1998
Same journal

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

Agents and actions. Supplements·1998
Same journal

A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

Agents and actions. Supplements·1998
See all related articles

Bradykinin and kinins are key players in inflammation. Targeting these molecules with new drugs, like bradykinin antagonists, offers promising treatments for inflammatory conditions.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Bradykinin and related kinins are central mediators in various inflammatory processes.
  • Understanding kinin production during injury, infection, and immune responses is crucial.

Purpose of the Study:

  • To discuss the mechanisms of kinin production in inflammation.
  • To highlight the therapeutic potential of bradykinin antagonists.

Main Methods:

  • Review of scientific literature on kinin pathways and inflammation.
  • Analysis of the role of bradykinin in different inflammatory conditions.

Main Results:

  • Kinins are significantly involved in mediating inflammation.
  • Mechanisms of kinin generation during injury, infection, and immune activation are elucidated.

Related Experiment Videos

Conclusions:

  • Bradykinin antagonists represent a promising therapeutic strategy for managing inflammation.
  • Further development of these antagonists could lead to novel anti-inflammatory drugs.